Vireo Growth Inc. filed a Form 425 on November 10, 2026, containing the transcript of its third-quarter 2026 earnings conference call, disclosing financial results for the period ended September 30, 2026, and providing forward-looking guidance for Q4 2026 and Q1 2027 in connection with its pending merger with Planet 13 Holdings Inc.
Key Highlights
- Q3 GAAP revenue: $253.7 million, up 177% year-over-year on a reported basis, according to the filing.
- Adjusted EBITDA: Approximately $42.7 million for Q3 2026, an improvement of $17.3 million or 68.1% over the same period last year.
- Balance sheet: Cash and cash equivalents of $106.8 million and long-term debt of $293 million at quarter end; net debt of $186.2 million excluding $23.4 million in convertible debt and cash.
- Share repurchases: 216,200 subordinate voting shares repurchased for approximately $2.5 million during Q3 under an NCIB program announced in August.
- Q4 2026 guidance: Revenue projected in the range of $250 million to $265 million and Adjusted EBITDA of $45 million to $48 million, excluding pending acquisitions.
- Q1 2027 guidance: Revenue expected in the range of $280 million to $300 million and Adjusted EBITDA of $53 million to $56 million, excluding pending acquisitions.
- Post-quarter financing: A $60 million real estate term loan with a U.S. commercial bank at a fixed rate of 8.5%, secured by cultivation and production facilities in New York and Florida.
Vireo Growth Reports Q3 Results and Outlines Acquisition-Driven Expansion
Vireo Growth Inc. hosted its Q3 2026 earnings conference call on November 10, 2026, at 8:00 a.m. ET. The filing, made pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, names Planet 13 Holdings Inc. (Commission File No. 000-56374) as the subject company. Chief Executive Officer John Mazarakis and Chief Financial Officer Tyson Macdonald led the call, disclosing that an Agreement and Plan of Merger between Vireo, Planet 13, and wholly owned subsidiary Supernova Merger Sub Inc. was entered into on July 26, 2026.
According to the filing, during the third quarter Vireo completed the acquisition of PharmaCann-Colorado, closed its acquisitions of C21 Investments (including Silver State operations) and M3 Wellness in Nevada, and entered into a management services agreement related to Cannabist assets in Colorado pending regulatory approval. Mazarakis further disclosed that the FLUENT acquisition in Florida closed on November 9, 2026, the day before the call. The company reported that pro forma Q3 revenue, giving effect to the PharmaCann Colorado, C21, and Cannabist Colorado MSA acquisitions as if completed on July 1, 2026, was $277.0 million, though this figure excludes FLUENT, remaining Cannabist assets, Planet 13, and the Ohio transactions. Pro forma year-over-year cannabis segment retail revenue growth was 4%, per the filing. Operating income improved by $13.9 million sequentially during the quarter.
Regarding guidance, Mazarakis stated the company is "providing a forward-looking outlook for revenue and adjusted EBITDA as a measure of profitability." The Q4 2026 outlook excludes pending acquisitions, but the filing noted those acquisitions, had they closed prior to the start of the quarter, could have contributed an additional $45 million to $55 million of revenue and $5 million to $6 million of Adjusted EBITDA. For Q1 2027, pending acquisitions could add $50 million to $60 million of revenue and $7 million to $8 million of Adjusted EBITDA. The company stated it will provide formal guidance on a sequential, quarterly basis only and will not provide full-year targets. The filing contains forward-looking statements, which the company noted are subject to risks and uncertainties and its cautionary language in public filings available on EDGAR and SEDAR+.
What Was Disclosed
Vireo Growth filed a Form 425 containing its Q3 2026 earnings call transcript, reporting $253.7 million in GAAP revenue, $42.7 million in Adjusted EBITDA, and providing revenue and Adjusted EBITDA guidance ranges for Q4 2026 and Q1 2027, alongside updates on multiple pending and completed acquisitions.



Please wait processing your request...